AEterna Zentaris (AEZS) Announces Publication of PI3K/Akt Article in Journal of Urology
More News related to AEZS
- Emerging Stock Report Initiates Independent Research Coverage on AEterna Zentaris Inc.
- Morning Movers 11/24: IWA, SEED, FEED, AEZS Higher; WH, ORS, ABIO, GRO, LONG Lower
- AEterna Zentaris (AEZS) Announces Phase 2 Results of AEZS-108 Endometrial Cancer Treatment
- AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
More News related to KERX
- Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
- AEterna Zentaris (AEZS) Reports That Perifosine Partner Keryx Biopharma (KERX) Will Prersent Data from Phase 1/2 at 51st ASH Meeting
- AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
- Keryx Biopharma (KERX) Posts Q3 EPS of 1c, Beats by 10c
More News related to Corporate News
- Maxim Group Initiates Coverage on Golden Green Enterprises (CHOP) with a Buy
- Hilliard Lyons Initiates Coveage on Approach Resources (AREX) with a Buy
- Wells Fargo Transfers Coverage on Intuitive Surgical (ISRG) to a Market Perform; Raises Valuation Range
- Wedbush Initiates Coverage on Coinstar (CSTR) with an Outperform
- Thomas Weisel Starts FARO Tech. (FARO) at Overweight, $24 Price Target
AEterna Zentaris Inc. (NASDAQ: AEZS) today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer. The article outlines the pivotal role of PI3K and Akt signaling pathways in renal cell carcinoma pathogenesis thus, representing an ideal target for therapeutic intervention. Perifosine is described as the most advanced PI3K/Akt pathway inhibitor, which has already proved to be clinically active, as well as an ideal compound to combine with other anticancer agents. Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), is AEterna Zentaris' partner and licensee for perifosine (KRX-0401) in the North American market.
The extensive article focuses on the role of the PI3K/Akt pathway in renal cell carcinoma pathogenesis, and on preclinical and clinical activity of compounds specifically targeting this pathway. Clinical data and perspectives on several compounds at different stages of development were also reviewed. The authors' conclusions on perifosine as a single agent or in combination therapy were based on data from several Phase 1 and Phase 2 studies in multiple types of cancer, including renal cell carcinoma.
Related Categories
Corporate NewsStocks Mentioned
+0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
